{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:58:41Z","timestamp":1793735921890,"version":"4.6.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>To evaluate the use of 2\u00a0mg intravitreal aflibercept for treatment of choroidal neovascularization (CNV) secondary to angioid streaks in patients with pseudoxanthoma elasticum (PXE).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>In this 12-month prospective, open-label, uncontrolled, non-randomized interventional clinical trial, 15 PXE patients with CNV (mean age: 53\u00a0years, range 22\u201365) received one initial intravitreal injection of 2\u00a0mg aflibercept. Further injections were based on CNV activity at monthly examinations. The primary endpoint was change of best corrected visual acuity (BCVA) after 12\u00a0months. Secondary outcomes were change of central retinal thickness (CRT), leakage from CNV, retinal sensitivity, and vision-related quality of life.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>BCVA improved from 75.0\u2009\u00b1\u200910.8 (\u00b1 SD, Snellen equivalent 20\/32) to 79.3\u2009\u00b1\u20097.3 ETDRS letters (20\/32) at final visit (<jats:italic>p<\/jats:italic>\u2009=\u20090.083). CRT decreased from 317\u2009\u00b1\u200981 to 279\u2009\u00b1\u200951\u00a0\u03bcm (<jats:italic>p<\/jats:italic>\u2009=\u20090.004). Retinal sensitivity on microperimetry changed from 17.8\u2009\u00b1\u20094.5 to 18.5\u2009\u00b1\u20094.3\u00a0dB (<jats:italic>p<\/jats:italic>\u2009=\u20090.103) and vision-related quality of life from a VQF-25 score of 80.7\u2009\u00b1\u200910.4 to 83.5\u2009\u00b1\u200914.5 (<jats:italic>p<\/jats:italic>\u2009=\u20090.554). The mean number of injections was 6.7\u2009\u00b1\u20092.6, and 5 participants had persistent or reactivated CNV activity at final visit. The observed adverse events were comparable with studies on aflibercept for other indications.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The results of this study indicate that intravitreal aflibercept is a treatment option for CNV secondary to PXE.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00417-019-04551-4","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T08:04:30Z","timestamp":1576829070000},"page":"311-318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Aflibercept for choroidal neovascularizations secondary to pseudoxanthoma elasticum: a prospective study"],"prefix":"10.1007","volume":"258","author":[{"given":"Martin","family":"Gliem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Birtel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Fimmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Coch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almut","family":"Wingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0351-6673","authenticated-orcid":false,"given":"Peter","family":"Charbel Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,20]]},"reference":[{"key":"4551_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/76102","volume":"25","author":"O Le Saux","year":"2000","unstructured":"Le Saux O, Urban Z, Tschuch C, Csiszar K, Bacchelli B, Quaglino D, Pasquali-Ronchetti I, Pope FM, Richards A, Terry S, Bercovitch L, de Paepe A, Boyd CD (2000) Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat Genet 25:223\u2013227","journal-title":"Nat Genet"},{"key":"4551_CR2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3389\/fgene.2012.00289","volume":"3","author":"O Le Saux","year":"2012","unstructured":"Le Saux O, Martin L, Aherrahrou Z, Leftheriotis G, V\u00e1radi A, Brampton CN (2012) The molecular and physiological roles of ABCC6: more than meets the eye. Front Genet 3:289","journal-title":"Front Genet"},{"key":"4551_CR3","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/ATVBAHA.114.304017","volume":"34","author":"RS Jansen","year":"2014","unstructured":"Jansen RS, Duijst S, Mahakena S, Sommer D, Szeri F, V\u00e1radi A, Plomp A, Bergen AA, Oude Elferink RPJ, Borst P, van de Wetering K (2014) ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report. Arterioscler Thromb Vasc Biol 34:1985\u20131989","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4551_CR4","doi-asserted-by":"publisher","first-page":"20206","DOI":"10.1073\/pnas.1319582110","volume":"110","author":"RS Jansen","year":"2013","unstructured":"Jansen RS, K\u00fc\u00e7\u00fckosmanoglu A, de Haas M, Sapthu S, Otero JA, Hegman IEM, Bergen AAB, Gorgels TGMF, Borst P, van de Wetering K (2013) ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release. Proc Natl Acad Sci U S A 110:20206\u201320211","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4551_CR5","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.ophtha.2009.11.008","volume":"117","author":"P Charbel Issa","year":"2010","unstructured":"Charbel Issa P, Finger RP, G\u00f6tting C, Hendig D, Holz FG, Scholl HPN (2010) Centrifugal fundus abnormalities in pseudoxanthoma elasticum. Ophthalmology 117:1406\u20131414","journal-title":"Ophthalmology"},{"key":"4551_CR6","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1167\/iovs.09-3541","volume":"50","author":"P Charbel Issa","year":"2009","unstructured":"Charbel Issa P, Finger RP, Holz FG, Scholl HPN (2009) Multimodal imaging including spectral domain OCT and confocal near infrared reflectance for characterization of outer retinal pathology in pseudoxanthoma elasticum. Invest Ophthalmol Vis Sci 50:5913\u20135918","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4551_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fgene.2013.00014","volume":"4","author":"M Gliem","year":"2013","unstructured":"Gliem M, de Zaeytijd J, Finger RP, Holz FG, Leroy BP, Charbel Issa P (2013) An update on the ocular phenotype in patients with pseudoxanthoma elasticum. Front Genet 4:14","journal-title":"Front Genet"},{"key":"4551_CR8","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1167\/iovs.16-19388","volume":"57","author":"M Gliem","year":"2016","unstructured":"Gliem M, M\u00fcller PL, Birtel J, Hendig D, Holz FG, Charbel Issa P (2016) Frequency, phenotypic characteristics and progression of atrophy associated with a diseased Bruch\u2019s membrane in pseudoxanthoma elasticum. Invest Ophthalmol Vis Sci 57:3323","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4551_CR9","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/ceo.13385","volume":"47","author":"J Birtel","year":"2019","unstructured":"Birtel J, Lindner M, Mishra DK, M\u00fcller PL, Hendig D, Herrmann P, Holz FG, Fleckenstein M, Gliem M, Charbel Issa P (2019) Retinal imaging including optical coherence tomography angiography for detecting active choroidal neovascularization in pseudoxanthoma elasticum. Clin Exp Ophthalmol 47:240\u2013249","journal-title":"Clin Exp Ophthalmol"},{"key":"4551_CR10","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1097\/IAE.0b013e3182914d2b","volume":"33","author":"M Gliem","year":"2013","unstructured":"Gliem M, Finger RP, Fimmers R, Brinkmann CK, Holz FG, Charbel Issa P (2013) Treatment of choroidal neovascularization due to angioid streaks: a comprehensive review. Retina 33:1300\u20131314","journal-title":"Retina"},{"key":"4551_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/1477-7525-9-113","volume":"9","author":"RP Finger","year":"2011","unstructured":"Finger RP, Fenwick E, Marella M, Charbel Issa P, Scholl HPN, Holz FG, Lamoureux EL (2011) The relative impact of vision impairment and cardiovascular disease on quality of life: the example of pseudoxanthoma elasticum. Health Qual Life Outcomes 9:113","journal-title":"Health Qual Life Outcomes"},{"key":"4551_CR12","doi-asserted-by":"crossref","unstructured":"Risseeuw S, Ossewaarde-van Norel J, Klaver CCW, Colijn JM, Imhof SM, van Leeuwen R (2018) Visual acuity in pseudoxanthoma elasticum. Retina (Philadelphia, Pa)","DOI":"10.1097\/IAE.0000000000002173"},{"key":"4551_CR13","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"J Holash","year":"2002","unstructured":"Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS (2002) VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393\u201311398","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4551_CR14","doi-asserted-by":"publisher","first-page":"1522.e1","DOI":"10.1016\/j.ophtha.2006.05.055","volume":"113","author":"QD Nguyen","year":"2006","unstructured":"Nguyen QD, Shah SM, Hafiz G, Quinlan E, Sung J, Chu K, Cedarbaum JM, Campochiaro PA (2006) A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113:1522.e1\u20131522.e14","journal-title":"Ophthalmology"},{"key":"4551_CR15","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548","journal-title":"Ophthalmology"},{"key":"4551_CR16","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","volume":"122","author":"Y Ikuno","year":"2015","unstructured":"Ikuno Y, Ohno-Matsui K, Wong TY, Korobelnik J-F, Vitti R, Li T, Stemper B, Asmus F, Zeitz O, Ishibashi T (2015) Intravitreal Aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. Ophthalmology 122:1220\u20131227","journal-title":"Ophthalmology"},{"key":"4551_CR17","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/eye.2015.283","volume":"30","author":"T Diago","year":"2016","unstructured":"Diago T (2016) Treat and extend regimen with aflibercept for choroidal neovascularization in angioid streaks. Eye 30:637\u2013639","journal-title":"Eye"},{"key":"4551_CR18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.4103\/0301-4738.167121","volume":"63","author":"E Esen","year":"2015","unstructured":"Esen E, Sizmaz S, Demircan N (2015) Intravitreal aflibercept for management of subfoveal choroidal neovascularization secondary to angioid streaks. Indian J Ophthalmol 63:616\u2013618","journal-title":"Indian J Ophthalmol"},{"key":"4551_CR19","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/eye.2016.28","volume":"30","author":"M Tetikoglu","year":"2016","unstructured":"Tetikoglu M, Sagdik HM, Aktas S, Ozcura F (2016) Intravitreal aflibercept for refractory choroidal neovascularization secondary to angioid streaks. Eye 30:894\u2013895","journal-title":"Eye"},{"key":"4551_CR20","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/eye.2015.92","volume":"29","author":"S Vaz-Pereira","year":"2015","unstructured":"Vaz-Pereira S, Colla\u00e7o L, de Salvo G, van Zeller P (2015) Intravitreal aflibercept for choroidal neovascularisation in angioid streaks. Eye 29:1236\u20131238","journal-title":"Eye"},{"key":"4551_CR21","doi-asserted-by":"publisher","unstructured":"Sekfali R, Mimoun G, Cohen SY, Querques G, Bandello F, Sacconi R, Souied EH, Capuano V (2019) Switching from ranibizumab to aflibercept in choroidal neovascularization secondary to angioid streaks. Eur J Ophthalmol. https:\/\/doi.org\/10.1177\/1120672119838133","DOI":"10.1177\/1120672119838133"},{"key":"4551_CR22","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","volume":"119","author":"CM Mangione","year":"2001","unstructured":"Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD (2001) Development of the 25-item national eye institute visual function questionnaire. Arch Ophthalmol 119:1050\u20131058","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"4551_CR23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ajo.2011.03.022","volume":"152","author":"Robert P. Finger","year":"2011","unstructured":"Finger RP, Charbel Issa P, Hendig D, Scholl HPN, Holz FG (2011) Monthly ranibizumab for choroidal neovascularizations secondary to angioid streaks in pseudoxanthoma elasticum: a one-year prospective study. Am J Ophthalmol 152:695\u2013703","journal-title":"American Journal of Ophthalmology"},{"issue":"8","key":"4551_CR24","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1097\/IAE.0000000000001744","volume":"38","author":"Timothy Y. Y. Lai","year":"2018","unstructured":"Lai TYY, Staurenghi G, Lanzetta P, Holz FG, Melissa Liew SH, Desset-Brethes S, Staines H, Hykin PG (2018) Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina 38:1464\u20131477","journal-title":"Retina"},{"key":"4551_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fgene.2013.00004","volume":"4","author":"G Lefth\u00e9riotis","year":"2013","unstructured":"Lefth\u00e9riotis G, Omarjee L, Le Saux O, Henrion D, Abraham P, Prunier F, Willoteaux S, Martin L (2013) The vascular phenotype in Pseudoxanthoma elasticum and related disorders: contribution of a genetic disease to the understanding of vascular calcification. Front Genet 4:4","journal-title":"Front Genet"},{"issue":"10","key":"4551_CR26","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jamaophthalmol.2019.2910","volume":"137","author":"Martin Gliem","year":"2019","unstructured":"Gliem M, Birtel J, M\u00fcller PL, Hendig D, Faust I, Herrmann P, Holz FG, Adamus G, Charbel Issa P (2019) Acute Retinopathy in Pseudoxanthoma Elasticum. JAMA Ophthalmol 137:1165\u20131173","journal-title":"JAMA Ophthalmology"},{"key":"4551_CR27","doi-asserted-by":"publisher","unstructured":"Hess K, Gliem M, Birtel J, M\u00fcller P, Hendig D, Andrews C, Murray IJ, Holz FG, Charbel Issa P (2019) Impaired dark adaptation associated with a diseased Bruch membrane in pseudoxanthoma elasticum. Retina. https:\/\/doi.org\/10.1097\/IAE.0000000000002689","DOI":"10.1097\/IAE.0000000000002689"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-019-04551-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-019-04551-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-019-04551-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,19]],"date-time":"2020-12-19T00:16:20Z","timestamp":1608336980000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-019-04551-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,20]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["4551"],"URL":"https:\/\/doi.org\/10.1007\/s00417-019-04551-4","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,20]]},"assertion":[{"value":"8 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Gliem is now employee and equity owner of F. Hoffmann-La Roche Ltd., Basel, Switzerland (since July 2019); he received financial support from Bayer AG and Heidelberg Engineering. Dr. Birtel received financial support from Heidelberg Engineering. Dr. Holz is consultant of Bayer AG, Heidelberg Engineering, and CenterVue. The Department of Ophthalmology, University Hospital of Bonn, Bonn, Germany, receives imaging devices from Heidelberg Engineering and CenterVue. Dr. Charbel Issa is consultant of Inozyme and received research support from Heidelberg Engineering. None of the authors has a proprietary interest in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study protocol and study documents were approved by the local ethics committee (Ethikkommission der Medizinischen Fakult\u00e4t, Rheinische Friedrich-Wilhelms-Universit\u00e4t Bonn; Lfd. Nr. 056\/15-AMG-ff). This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}